Literature DB >> 32038921

Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach.

Jacek Jassem1.   

Abstract

Entities:  

Year:  2019        PMID： 32038921      PMCID： PMC6987370          DOI： 10.21037/tlcr.2019.09.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  19 in total

1.  Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.

Authors:  Dongsheng Yue; Shidong Xu; Qun Wang; Xiaofei Li; Yi Shen; Heng Zhao; Chun Chen; Weimin Mao; Wei Liu; Junfeng Liu; Lanjun Zhang; Haitao Ma; Qiang Li; Yue Yang; Yongyu Liu; Haiquan Chen; Changli Wang
Journal:  Lancet Respir Med       Date:  2018-08-24       Impact factor: 30.700

2.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Jörg T Hartmann; Daniel Pink; Jochen Schütte; Giuliano Ramadori; Peter Hohenberger; Justus Duyster; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Maarit Sarlomo-Rikala; Bengt Nilsson; Harri Sihto; Odd R Monge; Petri Bono; Raija Kallio; Aki Vehtari; Mika Leinonen; Thor Alvegård; Peter Reichardt
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

3.  Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.

Authors:  Ning Li; Wei Ou; Xiong Ye; Hai-Bo Sun; Liang Zhang; Qin Fang; Song-Liang Zhang; Bao-Xiao Wang; Si-Yu Wang
Journal:  Ann Surg Oncol       Date:  2014-03-01       Impact factor: 5.344

4.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

5.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

6.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Authors:  Georgina V Long; Axel Hauschild; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Dirk Schadendorf; Thierry Lesimple; Ruth Plummer; Ran Ji; Pingkuan Zhang; Bijoyesh Mookerjee; Jeff Legos; Richard Kefford; Reinhard Dummer; John M Kirkwood
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

7.  EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials.

Authors:  Jing-Xun Wu; Qi He; Feng Ye; Qing-Xia Zhou; Hao-Jun Chen; Long Sun; Hua Wu
Journal:  Onco Targets Ther       Date:  2018-10-11       Impact factor: 4.147

8.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

9.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397

Review 10.  Third generation EGFR TKIs: current data and future directions.

Authors:  Chee-Seng Tan; Nesaretnam Barr Kumarakulasinghe; Yi-Qing Huang; Yvonne Li En Ang; Joan Rou-En Choo; Boon-Cher Goh; Ross A Soo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
View more
  2 in total

Review 1.  Targeting metastatic cancer.

Authors:  Karuna Ganesh; Joan Massagué
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

2.  Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis.

Authors:  Wenqian Li; Hanfei Guo; Lingyu Li; Jiuwei Cui
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.